ClinicalTrials.gg
CompletedNCT00452699Updated Dec 8, 2016Results posted

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

A Phase 4 interventional study of Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID and Fluticasone propionate 250 mcg BID in Asthma, sponsored by GlaxoSmithKline. Completed at 74 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-12-08.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
621
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
23rd of 146
621 · median 100
Started
2007
with 17 others
Phase 4
52 of 147
1 open now
Registered
33rd of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 23rd largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 52 in phase 4, and was the 33rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of asthma control will provide key information on the efficacy and safety of the combination therapy. The safety measure will be an assessment of adverse events

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • fluticasone propionate
  • long-term study
  • Salmeterol
  • FLOVENT 250
  • Asthma
  • ADVAIR 250
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects eligible for enrollment in the study must meet all of the following criteria:
  • Consent: A signed and dated written must be obtained from the subject and/or subject's legally acceptable representative prior to study participation.
  • Type of Subject: Outpatient
  • Gender: Male or female Females are eligible to participate only if they are currently non-pregnant and non-lactating.

A female is eligible to enter and participate in the study if she is:

  1. of non-; OR
  2. of child-bearing potential but has a negative urinary pregnancy test at Screening (Visit 1 and when specified in Appendix 1) and agrees to take precautions (including abstinence) which are adequate to prevent pregnancy during the study.

    Acceptable methods of contraception [Hatcher, 2004] are:

    • Abstinence
    • oral contraceptive (either combined or progestogen only)
    • injectable progestogen
    • implants of levonorgestrel
    • estrogenic vaginal ring
    • percutaneous contraceptive devices
    • intrauterine device (IUD) or intrauterine system (IUS) with published data showing that the lowest expected failure rate is less than 1% per year
    • male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject
    • double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent

      1. Age: A subject must be 12 years of age at Visit 1 (screening).
      2. Asthma Diagnosis: A documented diagnosis of persistent asthma, for at least six months, as defined by the following American Thoracic Society definition:

    Asthma is a clinical syndrome characterized by increased responsiveness of the airways to a variety of stimuli. The major symptoms of asthma are episodes of dyspnea, wheezing, and cough, which may vary from mild and almost undetectable to severe and unremitting (status asthmaticus). The primary physiological manifestation of this hyperresponsiveness is variable airway obstruction. This can take the form of spontaneous fluctuations in the severity of obstruction, substantial improvements in the severity of obstruction following bronchodilators or , or increased obstruction caused by drugs or other stimuli [American Thoracic Society, 1987].

    1. Asthma Medication History: A subject must be using a low to medium dose of an ICS (Table 1) OR a combination of controller medications (Table 2), containing a low (total daily) dose ICS (as defined in Table 1) for at least 4 weeks preceding screening.

    Table 1 (ICS Dosage Table) Inhaled Corticosteroid (Dosage (mcg/day))(LowMedium) Beclomethasone dipropionate CFC(168 = 504> 504 = 840) Beclomethasone dipropionate HFA (80 = 240>240 = 640) Triamcinolone acetonide(400 = 1000>1000 = 2000) Flunisolide (500 = 1000> 1000 = 2000) Fluticasone propionate inhalation aerosol (176 = 220> 220 = 440) Fluticasone propionate inhalation powder (100 = 250> 250 = 500) Budesonide1 (200 = 600> 600 =1200) Mometasone (200 = 400> 400 = 800) Ciclesonide (80 = 160>160 = 320)

    1.Respules are allowed at a dosage of 250-500mcg/day.

    Table 2 (Asthma Controller Medications) Asthma Controller Medication(s) Low dose ICS + Leukotriene modifiers Low dose ICS + Theophylline products Low Dose ICS + Inhaled anticholinergics or combination products (e.g., Atrovent or Combivent) Low Dose ICS + Long acting inhaled anticholinergic (e.g. Spiriva) Low dose ICS+ long acting beta agonist or combination products containing a low dose ICS and a long-acting beta-agonists (e.g. ADVAIR™/SERETIDE™1 100/50 mcg BID or Symbicort 160/9 mcg BID (i.e 80/4.5 mcg two inhalations BID)

    1. ADVAIR/SERETIDE =250/50 mcg BID or Symbicort 320/9 mcg BID (i.e 160/4.5 mcg two inhalation BID) are not permitted.
    2. Pulmonary function: A pre-albuterol (salbutamol) of 50% and 85% of predicted normal value at screening (Visit 1) after withholding asthma medications as detailed in the protocol (Section 6.8.1). Predicted FEV1 will be based on the National Health and Nutrition Examination Survey (NHANES III) predicted normal values for ages 8 years and older [Hankinson, 1999].
    3. Reversibility: An increase in FEV1 of 12% over the pre-albuterol (salbutamol) FEV1 within 30 minutes after the inhalation of 2-4 puffs of albuterol (salbutamol). Historical documentation of reversibility will not be permitted.
    4. Asthma symptom criteria: Each subject must have experienced asthma symptoms requiring albuterol (salbutamol) use within the 4 weeks preceding screening (Visit 1).

    Specific information regarding warnings, precautions, , adverse events, and other pertinent information on the product that may impact subject eligibility is provided in the IB and the product labels.

Exclusion criteria

Exclusion Criteria:

  • Subjects meeting any of the following criteria must not be enrolled in the study:
  1. Life-Threatening Asthma: A subject must not have life-threatening asthma. Life-threatening asthma is defined for this protocol as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, or hypoxic seizures, or asthma-related syncopal episode(s) within the 12 months prior to screening (Visit 1).
  2. Worsening of Asthma: A subject must not have experienced a worsening of asthma which involved an ER visit, hospitalization or use of oral/parenteral within 4 weeks of screening (Visit 1).
  3. Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only intermittent or seasonal or exercise-induced asthma are excluded from participation in this study.
  4. Concurrent Respiratory Disease: A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic bronchitis, emphysema, , or other respiratory abnormalities other than asthma.
  5. Concurrent Conditions/Diseases: A subject with historical or current evidence of any , co-morbid or uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study.

The list of excluded conditions/diseases includes, but is not limited to:

congestive heart failure known aortic aneurysm clinically significant coronary clinically significant cardiac arrhythmia heart disease stroke within 3 months of screening (Visit 1) uncontrolled hypertension coronary artery disease hematologic, hepatic, or renal disease cystic fibrosis poorly controlled peptic ulcer dyspnea by any other cause than asthma gastroesophageal reflux disease (GERD) not controlled by pharmacotherapy and may be causing/contributing to subject's respiratory symptoms thyrotoxicosis hypokalemia immunologic compromise current malignancy1 tuberculosis (current or quiescent) Cushing's or Addison's disease pneumonia, pneumothorax, chronic bronchitis or atelectasis uncontrolled diabetes mellitus recent history of drug or alcohol abuse 1) history of is acceptable only if subject has been in remission for one year prior to screening (Visit 1; remission = no treatment for the malignancy in the 12 months prior to screening [Visit 1])

  • Drug Allergy: A subject must not have had any immediate or delayed to any beta2-agonist; sympathomimetic drug; any intranasal; inhaled or systemic corticosteroid therapy; lactose; or have a severe milk protein allergy.
  • Respiratory Tract Infections: A subject must not have had any sinus, middle ear, oropharyngeal, upper or lower respiratory tract infection symptoms that have not resolved at least 7 days immediately preceding screening (Visit 1).

    1. Asthma Medications: Asthma medications listed below must not have been used prior to screening (Visit 1) for the required exclusion period as indicated below:

Medication (Exclusion Period Prior to screening (Visit 1)) Oral or parenteral systemic corticosteroids (4 weeks) Omalizumab (Xolair) (6 months)

  1. Concurrent Medications: A subject must not have the concurrent use of any of the following medications that interact with any of the study drugs used in this study, or that may affect the course of asthma or interact with sympathomimetic amines, such as:

    • beta-adrenergic receptor blocking agents
    • monoamine oxidase (MAO) inhibitors
    • tricyclic antidepressants
    • ritonavir
    • ketoconazole
  2. Concurrent use of asthma medications: Concurrent use of all asthma medications (other than protocol defined study and rescue medications and oral/parenteral corticosteroids) are prohibited during the study.
  3. Concomitant use of leukotriene modifiers (LTM) for allergies is prohibited. A subject must not be on LTM for treatment of nasal allergies that requires regular maintenance therapy. Substitution with any other antihistamine is permitted.
  4. Medications: A subject must not be using, or require the use of, immunosuppressive medications during the study.
  5. Immunotherapy for the treatment of allergies is not allowed during the study unless the subject has used a constant dose for 4 weeks prior to Screening (Visit 1) and the same dose will be continued throughout the study.
  6. Tobacco Use: >10 pack year history or use of any tobacco products within 1 year of screening (Visit 1). This includes cigarettes, cigars, pipe, chewing tobacco, and snuff.
  7. Questionable Validity of Consent: A subject must not have any infirmity or disability that would limit the subject's consent.
  8. Positive Pregnancy Test (for all females who have had menarche): A current positive pregnancy test.
  9. Medications: A subject must not have had use of any investigational drug within 30 days of screening (Visit 1).
  10. Site Affiliation: A subject may not participate if he/she is a participating investigator, sub-investigator, study coordinator, employee of a participating investigator or is in any way associated with the administration of the study. Immediate family members of these individuals are also excluded.
  11. Compliance with Study Requirements: A subject may not participate if, in the opinion of the investigator, there are present or anticipated circumstances that will prohibit the subject from being compliant with study visits and procedures (e.g. geographic location that will prohibit subject from required clinic visit schedule).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
621 participants (actual)

Study arms

  • Active comparator
    Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

    Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

    Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

  • Active comparator
    Fluticasone propionate 250 mcg BID

    Fluticasone propionate 250 mcg BID

    Drug: Fluticasone propionate 250 mcg BID

Interventions

  • DrugFluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

    Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

  • Fluticasone propionate 250 mcg BID

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52

    Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

    Time frame: Baseline and Week 1 through Week 52

Secondary outcomes

  1. Mean Change From Baseline in AM PEF Over Weeks 1-52

    Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

    Time frame: Baseline and Week 1 through Week 52

  2. Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52

    A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.

    Time frame: Baseline and Week 1 through Week 52

  3. Rate of Asthma Attacks Per Participant Per Year

    The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a 20% decrease in AM PEF, a 70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.

    Time frame: Week 1 through Week 52

07

Results

Posted Feb 15, 2010

Participant flow

Participant flow — Overall Study
MilestoneFSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 Weeks
Started306315
Completed225242
Not completed8173
Withdrew: Adverse event103
Withdrew: Lack of efficacy64
Withdrew: Lost to follow-up69
Withdrew: Protocol violation2125
Withdrew: Withdrawal by subject2625
Withdrew: Other127

Outcome measures

PrimaryMean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52

Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

Time frame:
Baseline and Week 1 through Week 52
Reported as:
Mean · Liters
Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52
LitersFSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 Weeks
Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-520.20 ± 0.0170.09 ± 0.015
Statistical analysis
  • FSC DISKUS 250/50 mcg BID for 52 Weeks vs FP DISKUS 250 mcg BID for 52 Weeks · ANCOVA · p = <0.001 · Least squares mean difference: 0.11 · 95% CI 0.07 to 0.15
SecondaryMean Change From Baseline in AM PEF Over Weeks 1-52

Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

Time frame:
Baseline and Week 1 through Week 52
Reported as:
Mean · Liters/minute (L/min)
Mean Change From Baseline in AM PEF Over Weeks 1-52
Liters/minute (L/min)FSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 Weeks
Mean Change From Baseline in AM PEF Over Weeks 1-5223.6 ± 2.479.8 ± 2.40
SecondaryMean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52

A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.

Time frame:
Baseline and Week 1 through Week 52
Reported as:
Mean · Percentage of symptom-free days
Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52
Percentage of symptom-free daysFSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 Weeks
Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-5237.1 ± 2.0228.5 ± 1.90
SecondaryRate of Asthma Attacks Per Participant Per Year

The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a 20% decrease in AM PEF, a 70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.

Time frame:
Week 1 through Week 52
Reported as:
Mean · attacks per participant per year
Rate of Asthma Attacks Per Participant Per Year
attacks per participant per yearFSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 Weeks
Rate of Asthma Attacks Per Participant Per Year1.87 (1.36 to 2.59)2.14 (1.55 to 2.96)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FSC DISKUS 250/50 mcg BID for 52 Weeks—14/306 (4.6%)183/306 (59.8%)
FP DISKUS 250 mcg BID for 52 Weeks—10/315 (3.2%)203/315 (64.4%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventFSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 Weeks
Asthma (exacerbation)Respiratory, thoracic and mediastinal disorders3/3060/315
PneumoniaRespiratory, thoracic and mediastinal disorders2/3060/315
Amoebic dysenteryInfections and infestations1/3060/315
SalmonellosisInfections and infestations1/3060/315
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/3060/315
Food poisoningInfections and infestations1/3060/315
Post procedural complicationInjury, poisoning and procedural complications1/3060/315
Ulna fractureMusculoskeletal and connective tissue disorders1/3060/315
Acute psychosisPsychiatric disorders1/3060/315
Deep vein thrombosisBlood and lymphatic system disorders1/3060/315
Most frequent other events
Most frequent other events
EventFSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 Weeks
Upper Respiratory Tract InfectionInfections and infestations62/30696/315
HeadacheNervous system disorders56/30659/315
NasopharyngitisInfections and infestations54/30656/315
BronchitisInfections and infestations20/30631/315
CoughRespiratory, thoracic and mediastinal disorders27/30619/315
SinusitisInfections and infestations17/30627/315
InfluenzaInfections and infestations22/30625/315
Back PainMusculoskeletal and connective tissue disorders20/30614/315
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders14/30620/315
Allergic RhinitisRespiratory, thoracic and mediastinal disorders13/30618/315

Baseline characteristics

Age, Continuous
Age, Continuous(years)FSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 WeeksTotal
Mean36.8 ± 15.5239.3 ± 15.5238.1 ± 15.55
Gender
Gender(Participants)FSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 WeeksTotal
Female191201392
Male115114229
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FSC DISKUS 250/50 mcg BID for 52 WeeksFP DISKUS 250 mcg BID for 52 WeeksTotal
White197208405
African American6361124
Asian394180
American Indian347
Other415
08

Study locations

74 sites
  • GSK Investigational Site
    Scottsdale, Arizona 85251, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Los Angeles, California 90095-1690, United States
  • GSK Investigational Site
    Rancho Mirage, California 92270, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    San Jose, California 95117, United States
  • GSK Investigational Site
    Denver, Colorado 80206, United States
  • GSK Investigational Site
    Denver, Colorado 80230, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80526, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80528, United States
  • GSK Investigational Site
    Stamford, Connecticut 06902, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Pensacola, Florida 32504, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Tamarac, Florida 33321, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Conyers, Georgia 30013, United States
  • GSK Investigational Site
    Lilburn, Georgia 30047, United States
  • GSK Investigational Site
    South Bend, Indiana 46617, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Bethesda, Maryland 20814, United States
  • GSK Investigational Site
    Wheaton, Maryland 20902, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    St. Louis, Missouri 63104, United States
  • GSK Investigational Site
    Billings, Montana 59102, United States
  • GSK Investigational Site
    Bozeman, Montana 59718, United States
  • GSK Investigational Site
    Omaha, Nebraska 68130, United States
  • GSK Investigational Site
    Cherry Hill, New Jersey 08003, United States
  • GSK Investigational Site
    Great Neck, New York 11023, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    Utica, New York 13502, United States
  • GSK Investigational Site
    Asheville, North Carolina 28801, United States
  • GSK Investigational Site
    High Point, North Carolina 27262, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Portland, Oregon 97213, United States
  • GSK Investigational Site
    Tigard, Oregon 97223, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15243, United States
  • GSK Investigational Site
    East Providence, Rhode Island 02914, United States
  • GSK Investigational Site
    Providence, Rhode Island 02906, United States
  • GSK Investigational Site
    Providence, Rhode Island 02909, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29309, United States
  • GSK Investigational Site
    Austin, Texas 78750, United States
  • GSK Investigational Site
    Corsicana, Texas 75110, United States
  • GSK Investigational Site
    El Paso, Texas 79925, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Houston, Texas 77054, United States
  • GSK Investigational Site
    Richmond, Virginia 23225, United States
  • GSK Investigational Site
    Richmond, Virginia 23229, United States
  • GSK Investigational Site
    Olympia, Washington 98506, United States
  • GSK Investigational Site
    West Allis, Wisconsin 53227, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1122AAK, Argentina
  • GSK Investigational Site
    La Plata, Buenos Aires 1900, Argentina
  • GSK Investigational Site
    Nueve de Julio, Buenos Aires B6500BWQ, Argentina
  • GSK Investigational Site
    Vicente López, Buenos Aires 1602, Argentina
  • GSK Investigational Site
    Buenos Aires, 1425, Argentina
  • GSK Investigational Site
    Buenos Aires, C1424BSF, Argentina
  • GSK Investigational Site
    Salvador, Bahía 41940455, Brazil
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • GSK Investigational Site
    Recife, Pernambuco 50670-420, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • GSK Investigational Site
    Mississauga, Ontario L4W 1N2, Canada
  • GSK Investigational Site
    Charlottetown, Prince Edward Island C1A 5Y9, Canada
  • GSK Investigational Site
    Saskatoon, Saskatchewan S7K 7H9, Canada
  • GSK Investigational Site
    Cavite, 4114, Philippines
  • GSK Investigational Site
    Lipa City, 4217, Philippines
  • GSK Investigational Site
    Quezon City, 1101, Philippines
09

References and documents

Publications

  • Anderson WH, Koshy BT, Huang L, Mosteller M, Stinnett SW, Condreay LD, Ortega H. Genetic analysis of asthma exacerbations. Ann Allergy Asthma Immunol. 2013 Jun;110(6):416-422.e2. doi: 10.1016/j.anai.2013.04.002. PubMed 23706709 ↗
  • Katial RK, Bernstein D, Prazma CM, Lincourt WR, Stempel DA. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. Allergy Asthma Proc. 2011 Mar-Apr;32(2):127-36. doi: 10.2500/aap.2011.32.3426. Epub 2010 Dec 28. PubMed 21189151 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2007
First posted
Mar 27, 2007
Start
May 2007
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Feb 15, 2010
Last update
Dec 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00452699
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 27, 2007
Start date
May 2007
Primary completion
May 2009
Completion
May 2009
Results posted
Feb 15, 2010
Last update
Dec 8, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion